Colistin’S Dark Face. Resurrection of Polymyxin Antibiotics and Alternative Strategies

Abstract
Due to the lack of new antibiotics for the treatment of critically ill patients with multidrug-resistant bacteria, interest on “old” antibiotics like colistin (polymyxin E) re-emerged. Colistin was initially used therapeutically in Japan and in Europe during the 1950s and in United States in the form of Colistimethate Sodium (CMS) in 1959. However, the intravenous formulations of colistin and polymyxin B were gradually abandoned in most parts of the world in the early 1980s because of the reported high incidence of adverse effects, nephro- and neurotoxicity. Colistin, is currently used as a last-line drug for the treatment of MDR Gram negative bacteria infection, so in the last fifteen years, this polymyxin has gained an important role as salvage therapy for patients infected with microorganisms susceptible only to colistin [1-4]. There is a dearth of information on the pharmacodynamics and toxicodynamics of colistin and its non-active prodrug CMS. Optimised dose regimens have not been establishment for different types of patients, especially in the critically ill population.

Keywords: Colistimethate Sodium; Multidrug-resistant bacteria (MDR); Encephalopathy; Extended spectrum beta lactamase (ESBL); β-lactamase inhibitors

Introduction
Due to the lack of new antibiotics for the treatment of critically ill patients with multidrug-resistant bacteria, interest on “old” antibiotics like Colistin (polymyxin E) re-emerged. Colistin was initially used therapeutically in Japan and in Europe during the 1950s and in United States in the form of Colistimethate Sodium (CMS) in 1959. However, the intravenous formulations of colistin and polymyxin B were gradually abandoned in most parts of the world in the early 1980s because of the reported high incidence of adverse effects, nephro- and neurotoxicity. Colistin, is currently used as a last-line drug for the treatment of MDR Gram negative bacteria infection, so in the last fifteen years, this polymyxin has gained an important role as salvage therapy for patients infected with microorganisms susceptible only to colistin [1-4]. There is a dearth of information on the pharmacodynamics and toxicodynamics of colistin and its non-active prodrug CMS. Optimised dose regimens have not been establishment for different types of patients, especially in the critically ill population.

Material and Methods
Regarding the metaphorical use of the dark face of colistin, we talk about its nephro and mainly neurotoxicity, especially in our post-surgical patients, moderate and severe encephalopathy and life-threatening respiratory paralysis caused by neuromuscular blockade. Recent reports have not described neurotoxicity associated with intravenous CMS, with the exception of cases in the cystic fibrosis population, among whom neurotoxicity has manifested as paresthesias and ataxia in 29% of patients treated (dosages in excess of 5 mg/kg per day). Our patient received intravenous CMS dosages 6 mg/kg per day. Only one case according most recent literature have described a profound encephalopathy with lack of brainstem reflexes in postsurgical patient [5]. 56-year-old man who developed renal, hematological and neurotoxicity on the 5 day after administration endovenous colistin and cefepima (CMS dosages of 160 mg/8 h, equivalent to approximately 6 mg/Kg per day). The patient has made perforated diverticulitis with descending colon resection and end colostomy left flank. On day 6 post-surgery nosocomial pneumonia by Pseudomonas Aeruginosa MR sensible to colistin was diagnosed. Electroencephalogram was compatible with severe encephalopathy. Peripheral eosinophil count had increased to 12%. He recovered promptly after stopping the drug.

Results and Discussion
The awareness of colistin’s potentially fatal effects must be kept in mind when we using. Vigilance of the encephalopathic picture can also facilitate the diagnosis of colistin-mediated neurotoxicity in a patient with altered mental status of otherwise unknown aetiology. The establishment of any relationships between the daily dosage of CMS, colistin levels, and neurological events is needed, especially in the critically post-surgical ill patient population.

It is contradictory that from the study of the most current works on colistin we can deduce that we are not using the correct dose: relatively poor potency and lung penetration, variable PK [6]. Dosing regimens do not allow high probability of achieving optimal exposures and we can’t increase dose due to toxicity so we get low PD exposures. Are postulated as probably more effective dose: loading dose of 9 MIU followed by a maintenance dose of 4.5 MIU/8-12h [7].

Finally, the increased use of colistin has resulted in the development of colistin-resistance. Adaptive or mutational mechanisms may play a role in resistance to colistin. Different gene mutations cause resistance by changing the outer membrane
of gram-negative bacteria. Colistin resistance in Pseudomonas Aeruginosa has been reported as 3% in the literature, no case in critical post-surgical patients [8-10].

Multidrug resistant P aeruginosa often requires complex antimicrobial regimens and, when treated inadequately, infections caused by this pathogen are associated with particularly poor outcomes including postoperative complications, longer hospital stays, and increased mortality. Until recently, ceftazidime was considered the most active cephalosporin against P aeruginosa strains; however this antimicrobial agent is affected by upregulation of efflux systems and by the acquisition of beta-lactamas.

Ceftolozane-tazobactam is an antibacterial consisting of ceftolozane, an antipseudomonal cephalosporin that has improved stability against the chromosomal AmpC produced by P Aeruginosa, and tazobactam, a penicillanic acid-sulfone beta-lactamasa inhibitor. Ceftolozane-tazobactam has been shown to be more active against resistant gram negative bacteria, especially P aeruginosa compared to cephalosporins, carbapenems and piperacillin-tazobactam, also in ESBL-producing enterobacteriaceae.

On the other hand, Avibactam is a new inhibitor of beta-lactamases. In vitro, it inhibits Ambler A class C (Amp C) enterobacteria and some class D enzymes (including OXA 48, except those produced by A Baumannii). Avibactam improves the activity of ceftazidime against ESBL-producing gram negative bacteria, carbapenemase type A (KPC), some type D (OXA) and class C of Ambler (AmpC) [11-13].

Conclusion

At the present time, the use of any antibiotic is associated with the potential development of tolerance or resistance from the first moment it is used. The burden of antibiotic resistance in gram-negative bacteria increases exponentially throughout the world and represents a global health problem.

It is crucial at this time to optimize antibiotics and their rational use. With the birth of the new beta-lactam/beta-lactamase inhibitors, Ceftolozane-tazobactam and Ceftazidime-avibactam, we can talk about a new horizon to combat multi-resistance in our time.

References